J&J Files for New Marketing Approvals for Stelara
Johnson & Johnson's Janssen Biotech has asked regulators in the U.S. and the European Union to approve its drug Stelara as a treatment for psoriatic arthritis.
The company says about 2 million people in the U.S. and 4.2 million in Europe have the condition. It is an autoimmune disease that causes joint inflammation and psoriasis skin lesions.
Stelara was approved in 2009 as a treatment for psoriasis. Over the last 12 months sales have grown 48 percent to $963 million.
Release Date: December 6, 2012
Source: The Associated Press